Effect of omalizumab therapy on coagulation parameters and total immunoglobulin e levels in patients with chronic idiopathic urticaria and bullous pemphigoid Kronik idiyopatik ürtiker ve büllöz pemfigoidli hastalarda omalizumab tedavisinin koagülasyon parametrelerine ve total immünoglobulin e düzeylerine etkisi
Turk Dermatoloji Dergisi, cilt.12, sa.4, ss.159-166, 2018 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 12 Sayı: 4
- Basım Tarihi: 2018
- Doi Numarası: 10.4274/tdd.3668
- Dergi Adı: Turk Dermatoloji Dergisi
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.159-166
- Anahtar Kelimeler: Anti-immunoglobulin E therapy, bullous pemphigoid, chronic urticaria, coagulation parameters, immunoglobulin E, omalizumab
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective: The aim of this study is to assess the impact of omalizumab on coagulation biomarkers and immunoglobulin E (IgE) levels in chronic idiopathic urticaria/chronic spontaneous urticaria (CIU/CSU) and bullous pemphigoid (BP) patients. Methods: Medical records of 31 CIU/CSU and 16 BP patients were reviewed according to the inclusion and exclusion criteria. Laboratory parameters for coagulation status and IgE levels at baseline and in the first 12-week period of omalizumab therapy were retrieved and analysed in the light of clinical response to the treatment. Results: At baseline, in CIU/CSU patients, IgE levels were significantly higher in responders [184.5 IU/mL (62-307 IU/mL)] than non-responders [25.6 IU/mL (10.8-30.2 IU/ mL)] (p=0.021). During the first 12 weeks of omalizumab therapy, a dramatic decrease in D-dimer levels was observed in serial measurements of CIU/CSU (p=0.001) and also BP patients (p=0.017). Total IgE levels were increased after omalizumab usage in all study groups (p=0.003) and elevation of IgE levels was found significant for CIU/CSU but not for BP (p<0.001, p=0.278, respectively). Conclusion: Baseline IgE levels may be used to predict which patients will gain benefit from omalizumab therapy in CIU/CSU group. During omalizumab therapy the plasma D-dimer levels show a dramatic decrease in the group of patients who responded of CIU/CSU and BP.